Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALDX | Aldeyra Therapeutics, Inc.

Index	RUT	P/E	-	EPS (ttm)	-0.89	Insider Own	2.80%	Shs Outstand	58.79M	Perf Week	-6.92%
Market Cap	394.68M	Forward P/E	-	EPS next Y	-1.09	Insider Trans	0.00%	Shs Float	46.06M	Perf Month	-15.17%
Income	-52.10M	PEG	-	EPS next Q	-0.33	Inst Own	64.90%	Short Float / Ratio	13.21% / 6.56	Perf Quarter	-18.13%
Sales	-	P/S	-	EPS this Y	0.70%	Inst Trans	-1.02%	Short Interest	6.09M	Perf Half Y	-14.94%
Book/sh	2.21	P/B	2.86	EPS next Y	5.20%	ROA	-30.00%	Target Price	20.38	Perf Year	3.10%
Cash/sh	2.43	P/C	2.60	EPS next 5Y	-	ROE	-35.90%	52W Range	4.95 - 11.97	Perf YTD	-9.20%
Dividend	-	P/FCF	-	EPS past 5Y	5.40%	ROI	-	52W High	-47.20%	Beta	1.09
Dividend %	-	Quick Ratio	10.00	Sales past 5Y	-	Gross Margin	-	52W Low	27.57%	ATR	0.29
Employees	15	Current Ratio	10.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	26.98	Volatility	4.11% 3.79%
Optionable	Yes	Debt/Eq	0.12	EPS Q/Q	49.90%	Profit Margin	-	Rel Volume	0.48	Prev Close	6.44
Shortable	Yes	LT Debt/Eq	0.08	Earnings	Aug 03 AMC	Payout	-	Avg Volume	927.25K	Price	6.32
Recom	1.40	SMA20	-12.37%	SMA50	-16.44%	SMA200	-21.02%	Volume	449,064	Change	-1.86%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-27-22	Resumed	H.C. Wainwright	Buy	$15
Feb-08-21	Initiated	H.C. Wainwright	Buy	$26
Dec-16-20	Initiated	Berenberg	Buy	$32
Oct-30-20	Initiated	Jefferies	Buy	$24
Oct-16-20	Initiated	BTIG Research	Buy	$29
Sep-22-20	Initiated	Alliance Global Partners	Buy	$32
May-12-20	Initiated	Oppenheimer	Outperform	$12
Dec-04-18	Initiated	Citigroup	Buy	$23
Sep-26-18	Reiterated	Cantor Fitzgerald	Overweight	$23 → $30
Sep-13-18	Initiated	Janney	Buy
Jan-26-18	Initiated	Seaport Global Securities	Buy	$13
Sep-26-16	Initiated	H.C. Wainwright	Buy	$18
Jul-01-16	Initiated	Stifel	Buy	$16
Jul-01-15	Initiated	Canaccord Genuity	Buy	$16
Mar-25-15	Initiated	Chardan Capital Markets	Buy	$16
Mar-20-15	Reiterated	H.C. Wainwright	Buy	$13 → $14
Nov-18-14	Initiated	H.C. Wainwright	Buy	$13
Jun-19-14	Initiated	Aegis Capital	Buy	$35

Show Previous Ratings

Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Jul-20-23 09:55AM	Can Aldeyra Therapeutics, Inc. (ALDX) Climb 107.66% to Reach the Level Wall Street Analysts Expect? (Zacks)
Jul-06-23 07:00AM	Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum (Business Wire)
Jun-29-23 07:00AM	Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX2191 in Patients with Retinitis Pigmentosa (Business Wire)
05:20AM	The Petri Dish: Startup behind VR treatments gets $16M, Aldeyra notches midstage trial win (American City Business Journals)
04:01PM	Loading…
Jun-28-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa (Business Wire)
Jun-27-23 12:03PM	Aldeyra Therapeutics' Chronic Cough Potential Shows Significant Reduction In Cough Frequency Versus Placebo (Benzinga)
07:00AM	Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX629 in Patients With Chronic Cough (Business Wire)
Jun-26-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX629 in Patients with Chronic Cough (Business Wire) +5.63%
Jun-23-23 07:00AM	Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes (Business Wire) -8.26%
Jun-21-23 09:34AM	Aldeyra Therapeutics Provides Regulatory Update on ADX-2191 (Business Wire) -27.44%
Jun-16-23 10:26AM	Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study (Zacks)
Jun-15-23 02:52PM	Why Aldeyra Therapeutics Stock Is Trading Higher Today (Benzinga)
07:08AM	Aldeyra Therapeutics eye treatment meets late-stage study main goal (Reuters)
07:00AM	Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE2 Trial of Reproxalap in Allergic Conjunctivitis (Business Wire)
04:01PM	Loading…
Jun-14-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE2 Trial in Allergic Conjunctivitis (Business Wire)
Jun-02-23 07:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (Business Wire)
May-07-23 07:30AM	This Biotech Is a Sight for Sore Eyes (TheStreet.com)
May-04-23 07:00AM	Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights (Business Wire)
Apr-13-23 07:00AM	Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis (Business Wire)
Apr-06-23 07:00AM	Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis (Business Wire)
Mar-30-23 07:00AM	Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough (Business Wire)
Mar-16-23 07:00AM	Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX2191 in Retinitis Pigmentosa (Business Wire)
Mar-11-23 02:59AM	Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 11:05PM	Q4 2022 Aldeyra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +7.19%
07:00AM	Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights (Business Wire)
Mar-02-23 07:00AM	FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma (Business Wire) +5.78%
Mar-01-23 07:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights (Business Wire)
Feb-28-23 03:22PM	Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients (Benzinga) -5.06%
07:00AM	Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease (Business Wire)
07:00AM	Loading…
Feb-23-23 07:00AM	Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy (Business Wire) +5.91%
Feb-22-23 05:26AM	Owning 40% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), (Simply Wall St.)
Feb-16-23 07:00AM	Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX629 Into New Phase 2 Systemic Disease Trials (Business Wire) +5.46%
Feb-09-23 07:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference (Business Wire)
Feb-07-23 07:00AM	Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease (Business Wire) +9.37%
Jan-12-23 06:37AM	Insiders made the right call by buying US$1.2m Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) stock this year, currently sit on US$349k profit (Simply Wall St.) +7.29%
Dec-21-22 07:00AM	Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX2191 for the Treatment of Primary Vitreoretinal Lymphoma (Business Wire) +6.23%
Dec-13-22 01:37PM	Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication (Benzinga)
08:00AM	Aldeyra Therapeutics Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial (Business Wire)
Dec-01-22 08:00AM	Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA (Business Wire) +10.00%
Nov-29-22 08:00AM	Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease (Business Wire) +5.00%
Nov-10-22 07:00AM	Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights (Business Wire) +6.18%
Nov-03-22 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights (Business Wire)
Nov-02-22 01:45PM	Aldeyra Therapeutics Is a Speculative Stock Worth a Small Position (TheStreet.com)
Oct-26-22 08:00AM	Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting (Business Wire) +7.81%
Oct-06-22 12:23PM	Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder (Benzinga)
07:00AM	Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy (Business Wire)
Oct-05-22 04:05PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy (Business Wire)
Sep-14-22 08:00AM	Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones (Business Wire)
Sep-07-22 08:00AM	Aldeyra Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Sep-01-22 06:56AM	Owning 48% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), (Simply Wall St.)
Aug-15-22 09:55AM	Aldeyra Therapeutics, Inc. (ALDX) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Aug-07-22 03:00AM	Aldeyra Therapeutics (ALDX) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-05-22 07:00AM	Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights (Business Wire) +10.90%
06:09AM	Joseph Edelman Just Bought 2.2% More Shares In Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Simply Wall St.)
Aug-01-22 02:55PM	Oppenheimer Says S&P 500 Could Rise Another 12% by Year-End and These Stocks Could Follow (TipRanks)
Jul-29-22 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights (Business Wire)
Jul-13-22 10:53AM	Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals (Zacks)
Jul-12-22 09:00AM	Aldeyra's Reproxalap Hits Primary Goals In Dry Eye Disease Chamber Crossover Trial (Benzinga) +14.99%
07:00AM	Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial (Business Wire)
Jul-11-22 04:05PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap (Business Wire)
Jun-28-22 12:20PM	Trade Alert: The CEO, President & Director Of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), Todd Brady, Has Just Spent US$60k Buying 2.4% More Shares (Simply Wall St.)
Jun-21-22 11:01AM	Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way? (Simply Wall St.) -5.07%
Jun-09-22 08:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (Business Wire) +10.29%
Jun-08-22 09:40AM	Why Aldeyra Therapeutics' Shares Are Soaring Today? (Benzinga)
07:00AM	Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease (Business Wire)
Jun-07-22 04:05PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease (Business Wire) +12.15%
May-24-22 07:00AM	Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease (Business Wire)
May-23-22 04:05PM	Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference (Business Wire)
May-18-22 03:26PM	Aldeyra's Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness (Benzinga) -6.82%
08:00AM	Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness (Business Wire)
May-05-22 08:30PM	Aldeyra Therapeutics (ALDX) Q1 2022 Earnings Call Transcript (Motley Fool) -5.12%
07:00AM	Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights (Business Wire)
May-04-22 08:30AM	Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting (Business Wire)
Apr-28-22 04:05PM	Aldeyra Therapeutics Announces Chief Financial Officer Transition (Business Wire) +8.31%
Apr-27-22 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights (Business Wire)
Apr-21-22 08:00AM	Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (Business Wire)
Apr-05-22 08:00AM	Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease (Business Wire)
Mar-29-22 08:00AM	Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day (Business Wire)
Mar-22-22 08:00AM	Aldeyra Therapeutics to Host R&D Day on Tuesday, March 29, 2022 (Business Wire)
Mar-18-22 07:30AM	Aldeyra Therapeutics (ALDX) Q4 2021 Earnings Call Transcript (Motley Fool)
Mar-17-22 07:00AM	Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights (Business Wire) +16.27%
Mar-14-22 08:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference (Business Wire) -8.54%
Mar-10-22 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2021 Financial Results and Discuss Recent Corporate Highlights (Business Wire)
Mar-08-22 08:00AM	Aldeyra Therapeutics Initiates Phase 2 Clinical Trial of ADX-2191 for the Treatment of Retinitis Pigmentosa (Business Wire) +8.80%
Mar-07-22 11:28AM	Could The Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ownership Structure Tell Us Something Useful? (Simply Wall St.) +7.14%
Feb-10-22 08:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference (Business Wire)
Feb-01-22 08:00AM	Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model (Business Wire)
Jan-18-22 01:38PM	HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ... (GuruFocus.com) -7.67%
Jan-11-22 08:00AM	Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra® (Business Wire)
Jan-07-22 01:38PM	Woodstock Corp Buys Amgen Inc, Applied Materials Inc, FedEx Corp, Sells Reata Pharmaceuticals ... (GuruFocus.com)
Jan-06-22 08:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference (Business Wire)
Jan-04-22 08:00AM	Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy (Business Wire)
Dec-29-21 10:18AM	Palatin (PTN) Begins Phase III Study For Dry Eye Disease (Zacks)
Dec-20-21 04:05PM	Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease (Business Wire)
Dec-15-21 08:38AM	Do Options Traders Know Something About Aldeyra (ALDX) Stock We Don't? (Zacks) +5.03%
Dec-05-21 06:23AM	Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Nov-11-21 08:38AM	Implied Volatility Surging for Aldeyra (ALDX) Stock Options (Zacks)
Nov-09-21 04:05PM	Aldeyra Therapeutics to Participate in Upcoming Conferences (Business Wire)
08:00AM	Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance (Business Wire)

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brady Todd C	President and CEO	Sep 07	Option Exercise	0.55	273,058	150,728	1,728,343	Sep 11 05:42 PM
Phillips Gary M.	Director	Sep 07	Option Exercise	0.55	5,437	3,001	14,812	Sep 11 04:31 PM
Walker Neal	Director	Aug 22	Option Exercise	0.55	9,604	5,301	15,854	Aug 24 04:13 PM
Bronstein Ben	Director	Jun 27	Option Exercise	0.55	9,604	5,301	28,248	Jun 29 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALDX | Aldeyra Therapeutics, Inc.

Upgrade your FINVIZ experience